SOHO 2023 | Emerging treatment options for lower- and higher-risk MDS and ongoing trials
Guillermo Garcia-Manero
• 9 Sep 2023
Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses treatment options emerging for patients with lower- and higher-risk myelodysplastic syndromes (LR/HR-MDS), commenting on recent approvals. Prof. Garcia-Manero also highlights the ongoing Phase III VERONA study (NCT04401748) and the need for more options in second-line HR-MDS. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
